{"links":{"html":"https://www.erudio.com/reports/evolve-lung02-nct05984277","json":"https://www.erudio.com/reports/evolve-lung02-nct05984277.json","markdown":"https://www.erudio.com/reports/evolve-lung02-nct05984277.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"evolve-lung02-05984277"}},"request":"https://www.erudio.com/contact?report=evolve-lung02-05984277"},"offer":{"cited_commentary_sources":10,"verified_hcp_statements":37,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"evolve-lung02-nct05984277"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=evolve-lung02-05984277","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/evolve-lung02-nct05984277","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T03:34:00.719725Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: source breakdowns; the limitations; the sample findings. The trial's registration date is now stated."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":1},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Overall Survival (OS), in PD-L1-negative participants."},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":4,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":7,"coverage":"discussed","id":"A1","source_count":6,"title":"Biomarker selection and limits of class-wide inference"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":1,"title":"Access, reimbursement and research participation"},{"claim_count":1,"coverage":"discussed","id":"A3","source_count":1,"title":"Earlier phase 1b response–safety trade-off"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":2,"title":"Disclosure and consequences for subsequent evidence generation"},{"claim_count":10,"coverage":"discussed","id":"A5","source_count":2,"title":"Commercial positioning and continuing programmes"},{"claim_count":4,"coverage":"discussed","id":"A6","source_count":1,"title":"Evidence thresholds for phase 3 entry"}],"counts":{"cited_sources":10,"claims_by_expression_type":{"comparison":1,"experience":1,"interpretation":11,"opinion":8,"question":2,"restatement":2,"uncertainty":2,"unspecified":10},"claims_by_kind":{"counterview":2,"interpretation":1,"source_observation":34},"clinician_statements":7,"evidence_units":24,"findings":6,"people_cited":12,"people_identity_verified":11,"people_total":14,"screened_sources":46,"verified_claims":37},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":6},"has_counterview":true,"limitations":2,"links":{"context":2,"support":9},"ma_question":true,"named_voices":5,"passages":7,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Futility raises a biomarker question without settling a mechanism-wide verdict"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":9},"ma_question":true,"named_voices":3,"passages":8,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Missing numerical efficacy and detailed safety data limit the lessons that can be drawn"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":2},"has_counterview":false,"limitations":1,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One clinician-facing development question is whether the phase 3 entry threshold was sufficient"},{"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":4,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Earlier interest in PD-L1-negative disease explains the rationale, but not the eventual result"},{"id":"F5","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Access constraints qualified enthusiasm and gave trial participation practical importance"},{"id":"F6","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":5},"has_counterview":true,"limitations":2,"links":{"context":1,"support":10},"ma_question":true,"named_voices":1,"passages":5,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"The episode's commercial verdict is stronger than its biological conclusion"}],"medical_affairs_question":"Before phase 3, should randomized added activity, stronger pharmacodynamic confirmation or a biomarker-defined population be required?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Futility, biomarkers and the limits of a class-wide verdict"},{"id":"section-2","level":2,"title":"Disclosure, tolerability and the cost of an unpublished failure"},{"id":"section-3","level":2,"title":"What evidence should precede phase 3?"},{"id":"section-4","level":2,"title":"Why low PD-L1 disease attracted interest"},{"id":"section-5","level":2,"title":"Access and the research–routine-care distinction"},{"id":"section-6","level":2,"title":"Commercial positioning is not a clinical mechanism result"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T2","label":"Primary endpoint: Overall Survival (OS), in PD-L1-negative participants."},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":4}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":3}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T03:34:00.719725Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T05:44:16Z","record_hash":"f3a017d9dc1bae1f7619cf90a86516f0e2b42fc738ce23e79476cd1cefadfb2c","release_hash":"ca76c7994c1ac52fb031a92ff3392db909e191bee468055ea0e2b5c3e6966251","report_id":"erudio-nct05984277","run_id":"eb8e9461-c9bd-4102-a928-80f6e293c462","schema_version":"5.0","slug":"evolve-lung02-05984277","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"eVOLVE-Lung02 asks whether volrustomig plus chemotherapy improves first-line treatment of metastatic non-small cell lung cancer compared with pembrolizumab plus chemotherapy. An X poster worries about implications for related checkpoint-blockade studies; on a podcast, a mechanism-wide verdict remains open. A LinkedIn poster welcomes the biological rationale, while efficacy and detailed safety reporting draw questions on the podcast. The same LinkedIn poster leaves the explanation for futility unresolved.","meta_description":"46 sources screened · 37 verified statements (7 from clinicians verified by NPI or staff page) from 10 sources · 6 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-33f3032ae9d4fbcb9ca8","claim-6824a08a0d4fff60a729"],"id":"F2","paraphrase":"A podcast asks which safety details should be available when interpreting eVOLVE-Lung02.","source_channel":"podcast","source_date":"2026-08-23","title":"Missing numerical efficacy and detailed safety data limit the lessons that can be drawn"},{"cited_claim_ids":["claim-12e3da89aeecf8b8b0a7","claim-95a35051e0562ff603d1"],"id":"F1","paraphrase":"A LinkedIn post addresses how to interpret eVOLVE-Lung02 in relation to checkpoint-blockade mechanisms and patient selection.","source_channel":"linkedin_post","source_date":"2026-08-24","title":"Futility raises a biomarker question without settling a mechanism-wide verdict"}]},"publication":{"approved_at":"2026-10-29T05:44:16Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T06:12:11Z","summary":"Corrected to match the delivered report: source breakdowns; the limitations; the sample findings. The trial's registration date is now stated."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":46},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","44 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion; source totals should not be read as numbers of independent clinicians.","The sources do not include a full protocol or an eVOLVE-Lung02 results publication. Announcement-based interpretations cannot establish numerical efficacy, detailed comparative safety or the reason for futility.","The episode's individual speakers are not identified in the transcript, so its views cannot be attributed to the named hosts.","The earlier phase 1b response and treatment-related-death comments concern a different study, and the relevant post is truncated.","Access statements describe the March 2024 discussion and do not establish current or uniform availability across countries.","Clinical roles are not confirmed for every named author. Strategic and investor-oriented observations should not be treated as HCP consensus.","Not yet captured in this edition: a view on the monitoring committee’s assessment of first-line treatment efficacy in metastatic lung cancer."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-08-24","start":"2023-08-11"},"retrieval_snapshot":"2026-10-29T03:01:55.349431Z","timeline":[{"count":1,"week":"2023-W32"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W36"},{"count":6,"week":"2026-W34"},{"count":1,"week":"2026-W35"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05984277:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05984277:context","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2ldgzgkb5gn7kfn35avzn7ai-3mtbqsqalrf26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4aeinxjwao74le6dktiiyxg4-3mtb5utdb6l2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7sx4xfvdi6ayikr76lbjpn4p-3mtijy2v4rc2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7sx4xfvdi6ayikr76lbjpn4p-3muuzlia52s2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mtbv5qotbs2k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3mtbtcds45v2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-l5aan5lkmuqstilgyczaho3v-3mtbry44emc2p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mtfctq4q7pnrabqbzmjomz5z-3mtces5gf2j2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pko5fzgbs5p5upqhkrv5w7vt-3llxya6cch22b","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7496789245890592770","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7497599490049150976","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ebad9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1590636274033229824:be093106-8a46-4ff6-aeba-3a6199badabf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1769681724030456203:fa96424a-f670-415a-97c5-ee776c10f888","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1830430271625425235:c7e40741-adc9-4c28-ba4c-7a6cbdd9e444","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833975322876019016:76f2901b-6ab4-4a9d-a5a6-439307dee8f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965042923046633535:65c72181-4c5f-4322-8523-0d3c26b66159","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089234657065799994:b24701c3-e1c0-47c8-a8ef-0ecc25d42f59","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089238135645585905:6beeb1ec-eafb-4d72-a0c0-a72f3235979a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089238596213744062:e225d1a7-70ca-4829-984f-aadf60535d4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089243290059354367:c0b07c2e-5d20-4efd-bac7-cf9e68eb3c78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089249125699063907:922a9c2d-e801-4dbd-af96-e8c3ca3c1067","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089250102443446442:22499f4f-1081-4450-8f06-9f027603b38e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089253663487209689:3b6d290e-64e3-42d6-a71d-f3e660a96240","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089261703837975028:165a2fc6-9bff-44b3-b2ce-cd1f4cb106e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089286294035636397:ce7f1176-5c8f-44bb-88b1-889f77f509ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089289256405553269:4a388014-f053-44d4-a859-e69c932c74b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089323897069977944:d99e67eb-bd20-4168-9a51-2acd7e165d1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089335445381353905:156e3fc1-0e9a-4225-9df5-8228db260ed5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089354977864990779:f40168d4-e7be-49cb-b765-3dfdbee1678a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089356555049382181:aac46e72-0934-4e31-96f1-b98ee4879d79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089360850335199650:de882d29-e0eb-44cd-8e30-4bac3efe2273","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089365725521522897:7441b9c5-ec12-4c0c-a60e-297d98e5bc45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089385665167556728:ae9429f6-5556-4bd7-95f1-3d06cffc0ba3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089392425546477735:53a14eb0-c3cb-4bdb-9854-234248aa0064","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089431449133011065:0498d8cd-fb76-4729-b952-ee2057d33ecb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089515141821800742:413c0024-17ab-4888-8b1d-1dc0a6f8976b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089633404438340025:548dcdad-7e82-4d55-b019-3b256df916dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089656311776702770:12fab51b-ec4c-4303-8b31-5a9898010a40","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089759229837996325:cdcbb24e-f0cc-4fdb-a618-9753c27539ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089802228680810685:83da9219-b20b-403a-aa48-faf44cbb6492","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090363640759341435:f58815e8-58ca-43ff-a6ff-bdcd4117da34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091948712587325451:9fd9ac78-7c01-4427-8e4d-5c087f17bc4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094138080730955815:19e877dc-73d6-41e3-ab2a-dc50fe3e3621","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108999379960967447:c5ae38fb-9dd5-4e0d-aae3-6c3e4e1d524e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115630463423271293:56687914-f74d-4cad-923f-52f5477280a8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":9,"linkedin_post":2,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":34,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":46},"count":46,"evidence_window":{"end":"2026-10-29","start":"2023-08-11"},"retrieval_snapshot":"2026-10-29T03:01:55.766095Z","timeline":[{"count":1,"week":"2023-W32"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W36"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2025-W14"},{"count":1,"week":"2025-W37"},{"count":34,"week":"2026-W34"},{"count":3,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: volrustomig","status":"unmapped"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"eVOLVE-Lung02","aliases":["eVOLVE-Lung02","A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.","A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC)."],"brief_title":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":{"count":895,"type":"ACTUAL"},"interventions":[{"name":"Volrustomig","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Paclitaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05984277","official_title":"A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-08-17","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization until radiological progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression), in PD-L1-negative participants.","measure":"Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)","timeFrame":"Up to approximately 6 years"},{"description":"OS is defined as the time from randomization until the date of death due to any cause, in PD-L1-negative participants.","measure":"Overall Survival (OS), in PD-L1-negative participants.","timeFrame":"Up to approximately 6 years"}],"registered_date":{"date":"2023-08-09","type":"ACTUAL"},"registry_last_updated":"2026-10-09","registry_url":"https://clinicaltrials.gov/study/NCT05984277","short_name":"eVOLVE-Lung02","short_name_basis":"registry_acronym","sponsor":"AstraZeneca","start_date":{"date":"2023-10-24","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"D798AC00001","type":"sponsor_study_id"},{"id":"2023-000056-38","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}